Executive Summary
This digest covers five contracts totaling $1.597 billion, with only one defense-related award (20% of records) and the remainder civilian, primarily from HHS and NASA. The dominant theme is stable, multi-year IT and biodefense spending, with CACI's $674M GSA IT services contract as the highest-conviction signal, offering predictable cost-plus revenue through 2024.
Key risks include the expired Teledyne Brown NASA contract ($371.5M) with no follow-on visibility and the nonprofit Sabin Vaccine Institute award ($263.6M) limiting direct equity exposure. Investors should monitor CACI's contract execution and potential recompete, as well as BARDA's option exercises for biodefense funding continuity.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior General Federal Contracts digest from August 20, 2026.
Investment Signals (5)
- CACI Wins $674M GSA IT Services Contract, Strengthening Federal IT Position (HIGH)▲
CACI secured a $674.4M cost-plus-fixed-fee delivery order from GSA for IT and telecom services under the Communication and Information Technology Services III program, with low pricing risk and full competition win.
- Teledyne Brown's $371.5M NASA Contract Expired Without Clear Follow-On (HIGH)▲
Teledyne Brown Engineering's NASA ISS mission operations contract ended in December 2022 with only $151.3M outlayed (41% of obligated value), indicating under-execution and zero future revenue contribution unless follow-on work is awarded.
- BARDA Awards $263.6M to Sabin Vaccine Institute for Marburg Virus R&D (MEDIUM)▲
The Albert B. Sabin Vaccine Institute received a $263.6M cost-plus-fixed-fee contract from BARDA (HHS) for Marburg virus advanced R&D, with a total potential value of $1.04B over 10 years, signaling sustained biodefense investment.
- HSGS-AMERESCO's $149.2M VA ESPC Contract Carries Fixed-Price Execution Risk (MEDIUM)▲
HSGS-AMERESCO won a $149.2M firm-fixed-price delivery order from the VA for energy savings performance work, with high pricing risk due to fixed-price structure and reliance on energy savings verification.
- HIGHRISE Consulting's $138.6M NIH IT Contract Shows Strong Execution (HIGH)▲
HIGHRISE Consulting has outlayed $89.6M (65%) of its $138.6M NIH IT delivery order, indicating high utilization and low cancellation risk through September 2027.
Risk Flags (4)
- Execution [HIGH RISK]▼
Teledyne Brown's NASA contract had only $151.3M outlayed against $371.5M obligated, suggesting under-execution or delayed spending; no follow-on contract identified after 2022 end date.
- Budget [MEDIUM RISK]▼
CACI's $674.4M GSA contract has a negative net outlay (-$414,919), which is unusual and may indicate accounting adjustments or early-stage activity; contract ends May 2024 with recompete risk.
- Concentration [MEDIUM RISK]▼
HSGS-AMERESCO's $149.2M VA contract is an SDVOSB set-aside, limiting scalability and competition; fixed-price structure adds execution risk for energy savings performance.
- Regulatory [MEDIUM RISK]▼
Sabin Vaccine Institute contract is with a nonprofit, limiting direct equity investment; BARDA budget priorities could shift, affecting long-term funding for Marburg virus R&D.
Opportunities (4)
- ◆
CACI's $674M GSA IT contract demonstrates strong competitive positioning in federal IT; recompete or extensions could provide additional revenue visibility beyond May 2024.
- ◆
HIGHRISE Consulting's high utilization (65% outlayed) on its $138.6M NIH IT contract suggests potential for additional task orders or follow-on work in cloud computing.
- ◆
BARDA's $1.04B potential value contract for Marburg virus R&D could generate subcontract opportunities for publicly traded biotech firms in vaccine development.
- ◆
HSGS-AMERESCO's SDVOSB set-aside contract with the VA signals policy alignment; future VA ESPC task orders could provide recurring revenue for SDVOSB firms.
Sector Themes (3)
- ◆
Two contracts totaling $813M (CACI $674M and HIGHRISE $138.6M) highlight sustained demand for IT and cloud services from civilian agencies like GSA and NIH, with cost-plus and labor-hours pricing reducing margin risk.
- ◆
BARDA's $263.6M award to Sabin Vaccine Institute for Marburg virus R&D, with a $1.04B potential value, underscores continued government commitment to biodefense and emerging infectious disease preparedness.
- ◆
Teledyne Brown's $371.5M NASA contract for ISS mission operations support, now expired, reflects the maturation of manned spaceflight operations; future opportunities may shift to commercial space stations.
Watch List (5)
- 👁
{"entity" => "CACI International Inc.", "reason" => "CACI's $674M GSA IT contract ends May 2024; recompete risk and negative outlay require monitoring.", "trigger" => "GSA recompete announcement for Communication and Information Technology Services III"}
- 👁
{"entity" => "Teledyne Technologies", "reason" => "Teledyne Brown's $371.5M NASA contract expired in 2022 with no clear follow-on; space segment revenue may decline.", "trigger" => "NASA ISS mission operations follow-on contract awards"}
- 👁
{"entity" => "Albert B. Sabin Vaccine Institute", "reason" => "Nonprofit recipient of $263.6M BARDA contract; subcontract awards to public biotech firms could create investment opportunities.", "trigger" => "Subcontract awards to publicly traded biotech firms"}
- 👁
{"entity" => "HSGS-AMERESCO, LLC", "reason" => "Fixed-price VA ESPC contract carries execution risk; option exercise by February 2027 is key catalyst.", "trigger" => "Option exercise by February 2027"}
- 👁
{"entity" => "HIGHRISE CONSULTING INC", "reason" => "High utilization on $138.6M NIH IT contract suggests potential for additional task orders; monitor NIH IT budget.", "trigger" => "NIH budget allocations for IT and cloud services"}
Get daily alerts with 5 investment signals, 4 risk alerts, 4 opportunities and full AI analysis of all 5 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: General Federal Contracts
🇺🇸 More from United States
View all →August 21, 2026
Insider Trading Pulse — August 21, 2026
Insider Trading Pulse
August 21, 2026
US Merger & Acquisition SEC Filings — August 21, 2026
US Merger & Acquisition SEC Filings
August 21, 2026
USA Insider Trading Pulse — August 21, 2026
USA Insider Trading Pulse
August 21, 2026
USA Corporate Actions — August 21, 2026
USA Corporate Actions